Tower Research Capital LLC (TRC) quarter change: Foreign ADRs, Sold out
In depositary receipts for foreign shares (depositary receipts and foreign shares traded over the counter), from the quarter ended 2026-03-31 to 2026-06-30, Tower Research Capital LLC (TRC) opened 2 positions, added to 1, reduced 0, sold out of 2 and left 0 unchanged. The largest increase in value was QUHUO LTD (+$27,762); the largest decrease was ASCENDIS PHARMA A/S (-$39,113).
- ASCENDIS PHARMA A/S: Country of operation —; Class SPONSORED ADR; Shares 2026-03-31 171; Shares 2026-06-30 0.
- LIXIANG ED HLDG CO LTD: Country of operation —; Class SPONSORED ADR; Shares 2026-03-31 15,000; Shares 2026-06-30 0.
Two Form 13F-HR filings compared (SEC CIK 1533421): 2026-03-31 (filed 2026-05-15) and 2026-06-30 (filed 2026-08-11). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move; share change is the position change.
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|---|---|---|
| H&F Corporate Investors X, Ltd. | United States | $3.848B | 1 |
| Destination Wealth Management | United States | $3.851B | 342 |
| Americana Partners, LLC | United States | $3.851B | 510 |
| TRIAN FUND MANAGEMENT, L.P. | United States | $3.860B | 9 |
| Anther Capital Ltd | Hong Kong | $3.826B | 31 |
| Greenwoods Asset Management Hong Kong Ltd. | Hong Kong | $3.878B | 35 |
| Interval Partners, LP | United States | $3.818B | 262 |
| TOMS Capital Investment Management LP | United States | $3.814B | 19 |
| Frazier Life Sciences Management, L.P. | United States | $3.887B | 38 |
| American Family Investments, Inc. | United States | $3.803B | 13 |